23 Jan AviadoBio
Lisa Deschamps, CEO and Board Member
April 28 | 2:00pm | Salone dei Cavalieri, Section 1
London, UK
(Private)
AviadoBio is relentlessly chasing cures and delivering hope to families living with neurodegenerative disease. We are developing one-time gene therapies that are built on scalable, targeted delivery technology designed to overcome the biological challenges of treating neurological diseases, prioritizing precision, efficacy and safety. AviadoBio’s pipeline includes programs for frontotemporal dementia (FTD), inherited retinal dystrophies such as retinitis pigmentosa, and tauopathies, including Alzheimer’s disease. The company is committed to advancing therapies that target complex neural systems across the brain, spinal cord, and retina using proprietary capsid engineering and our novel best in class vMiX RNA gene silencing platform. The company has raised over $160 million to date and last year signed an exclusive option and license agreement with Astellas Pharma for AVB-101. Under the terms of the agreement, Astellas provided a $50 million upfront and if exercised up to $2.2 billion in license fees and milestone payments plus royalties.
